Scott E. McNeil

Scott E. McNeil is the director of the National Cancer
Institute’s Nan-otechnology Characterization Laboratory
(NCL). The NCL conducts preclinical characterization of
nanotechnology-based cancer therapeutics and diagnostic imaging agents.
This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
contract HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U.S. Government. The
author thanks Jennifer Hall for considerable help in preparation of this
commentary.